Read end-to-end by a FundingAtlas editor against the official source.
Quick answer
British Patient Capital provides indirect equity for high-growth UK companies via the venture and growth funds it backs — not direct investment. Founders raise from BPC-backed managers in the normal way. The programme exists to deepen UK long-term capital across life sciences, deep tech, climate and digital. Most relevant after Series A, when a company is targeting a £10m+ growth round and wants UK-anchored, longer-duration capital alongside international syndicate partners.
Funding amount
Varies
Region
United Kingdom
Stage
Growth
Provider
British Business Bank — British Patient Capital
Advisor view
British Patient Capital is a subsidiary of the British Business Bank. It is a fund-of-funds: it commits capital to UK-focused venture and growth funds, which then invest in companies. For founders, the practical implication is that you never "apply" to British Patient Capital — you build a relationship with the underlying funds in its portfolio, the same way you would with any other VC. The strategic value of knowing about British Patient Capital is two-fold: (1) it materially expands the pool of UK-active growth capital, which is structurally thinner than in the US, and (2) the published portfolio is a high-quality, curated list of UK-investing funds you can map against your stage and sector.
Frequently asked questions
- Can my company apply to British Patient Capital directly?
- No. BPC invests in venture and growth funds, not into operating companies. You raise from a BPC-backed fund using its normal investment process.
- How do I tell which funds are BPC-backed?
- The British Patient Capital portfolio page lists the underlying fund managers it commits to. Use it as a shortlist when planning your raise.
- Does a BPC-backed fund have to invest in the UK?
- BPC capital is mandated to support UK economic activity, so the funds it backs concentrate on UK-headquartered or UK-substantive companies.
- What round sizes are typical?
- BPC-backed managers operate across the spectrum from Series A through growth, with cheques typically from a few million pounds up to tens of millions depending on the fund.
- Is BPC the same as the British Business Bank?
- BPC is a subsidiary of the British Business Bank focused specifically on venture and growth equity, separate from the Bank's debt and guarantee programmes.
- Does BPC influence which deals its funds back?
- Underlying fund managers make their own investment decisions. BPC is a limited partner, not a co-investor on every deal.
- Does BPC support secondary transactions?
- BPC capital can flow into funds that participate in secondaries, but founders should treat secondaries as a fund-by-fund question rather than a BPC product.
- How does BPC compare to Enterprise Capital Funds?
- ECFs target the earlier-stage equity gap with a heavier public commitment; BPC focuses on later-stage venture and growth fund-of-funds activity.
- Can BPC capital be combined with Innovate UK grants?
- Yes — many BPC-backed portfolio companies also hold Innovate UK grants. Investor Partnerships specifically pairs grant and equity.
- Does a BPC-backed lead change deal terms?
- Deal terms reflect the underlying manager's standard documents and the market for the round; BPC backing does not impose specific company-level terms.
Who it's for
High-growth UK-headquartered companies — typically post-Series A through growth stage — that are raising equity from institutional venture or growth funds. Sector coverage is broad but skews toward tech, life sciences, deep-tech and other capital-intensive scale-ups.
Probably not for you if…
Pre-seed founders, lifestyle businesses, companies seeking grant funding, and any business looking to apply to British Patient Capital directly — it does not invest into companies. Companies that are not investment-ready (no traction, no team, no defined market) should not approach the underlying funds yet.
Usually too early when
Advisor signal
You are pre-revenue with no defined product, no team, and no investor-ready data room. Patient capital funds typically engage with companies that already have a Series A profile — meaningful revenue or technical milestones, a credible team, and a defined route to a large market.
Eligibility
High-growth UK companies backed by funds in the British Patient Capital portfolio. No direct applications.
Evidence you'll need
Investment-grade pitch deck, financials and KPI traction; standard fund due diligence.
Application timeline
There is no central British Patient Capital application. Engagement with each underlying fund typically runs 3–9 months from first meeting to term sheet, plus a further 4–12 weeks of diligence and legals to close. Plan investor processes well in advance of when you need the cash.
Common reasons applications fail
Approaching the wrong stage of fund, weak or generic outreach, an unconvincing data room, unrealistic valuation expectations, founder team gaps, and a market thesis the fund does not believe is large or defensible enough.
What improves your odds
Map yourself against specific funds in the British Patient Capital portfolio (stage, sector, cheque size) rather than approaching the whole list. Have a clean data room, a credible 5-year plan, and ideally a warm introduction. Build relationships 6–12 months before you need to close. Where relevant, use prior Innovate UK grants and SEIS/EIS rounds as proof points of capital efficiency.
Typical successful applicant
A UK-headquartered scale-up with a strong technical or market moat, an experienced leadership team, demonstrable traction (revenue or hard technical milestones), and a credible plan to deploy £2m–£50m+ of equity to capture a defined large market.
Common misconceptions
- "You apply to British Patient Capital." You do not — you raise from its portfolio funds. - "It's a UK government grant scheme." It is institutional equity via a government-backed investor. - "It's for early-stage startups." Most underlying funds invest from Series A upwards; deep-tech and life-sciences specialists may go earlier but still expect investor-grade evidence. - "Being UK-based is enough." Stage, sector fit and quality of team and traction matter at least as much as geography.
What happens next
Review the British Patient Capital portfolio of funds and shortlist those whose stage, sector and cheque size match your raise. Approach them directly — ideally via a warm introduction from another founder, an existing investor, or an Innovate UK Business Growth specialist. Run a structured process across several funds in parallel rather than sequentially.
What comes next
After a first round from a British Patient Capital portfolio fund, the typical progression is (a) follow-on rounds led by the same fund or syndicated with international growth investors, (b) parallel non-dilutive support via Innovate UK Smart Grants or Innovation Loans to extend runway between rounds, or (c) eventual exit via trade sale or IPO — the long-hold nature of patient capital is designed to support these multi-year journeys rather than push for early liquidity.
Funding context
This is equity, not grant. Expect dilution, board involvement, full investor diligence and a multi-year relationship. British Patient Capital's remit specifically addresses the UK's "patient capital" gap — longer-hold growth funding for companies that need 7–10+ years to scale, particularly in deep-tech and life sciences. Cheque sizes from the underlying funds typically range from low millions to tens of millions, depending on fund and stage.
Related routes
Industries
Objectives
Regions